Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. - Bibi, David; Steiner, Lilach; Krtalic, Iva; Juretic, Marina; Cetina-Cizmek, Biserka; Komlosi, Andrea; Loupe, Pippa; Ferderber, Kristina; Hallak, Hussein (Pharmaceutics, 2026)